Newsstand | Aplastic Anemia & MDS International Foundation Return to top.

Newsstand

Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

COVID-19 vaccination for hematopoietic stem cell transplant patients

Originally Published: 05/14/2021
The SARS-CoV-2 pandemic has changed the world over the last year and impacted almost every part of our lives. In particular, patients with hematologic malignancies have been significantly affected by this crisis at every stage of their treatment. Delays in diagnosis and increased waiting times for transplants and therapy have become common occurrences. Patients with hematologic malignancies are also more likely to suffer from severe COVID-19, leading to a greater mortality rate. A recent meta-analysis of 3,377 patients with hematologic malignancies and COVID-19 showed a mortality rate of 34...

Participation of Black Americans in Cancer Clinical Trials: Current Challenges and Proposed Solutions

Originally Published: 05/11/2021
ABSTRACT Low participation of Black Americans in cancer clinical trials is a well-established predicament. Many factors resulted in this current dilemma with racism being the fundamental unit. Here, we discuss some current challenges and proposed solutions to help in increasing the enrollment of Black Americans in cancer clinical trials. We suggest implementing the least acceptable race-specific percentage as a new bar that registrational clinical trials need to pass before cancer drugs approval. Clinical trials will continue to draw the future of cancer therapeutics in which we believe that...

Researchers Uncover How MN1 Overexpression Causes AML

Originally Published: 05/10/2021
Meningioma-1 (MN1) is a protein whose overexpression has been linked to acute myeloid leukemia (AML) and brain tumors, and 70% to 80% of AML patients with high overexpression of MN1 die within two years. Yet the mechanism by which MN1 causes these diseases has largely remained a mystery. “Looking at the sequence, the protein has no obvious structure,” said Kathrin M. Bernt, MD, a pediatric oncologist in the Cancer Center’s Leukemia and Lymphoma Program at Children’s Hospital of Philadelphia (CHOP). “MN1 doesn’t resemble other typical oncogenes – or any other proteins – so it’s difficult to...

Unmet Needs of Individuals Living with Higher-Risk Myelodysplastic Syndromes: Perspectives from the Global Patient Advocacy Community

Originally Published: 05/03/2021
In 2019, an in-depth Global Myelodysplastic Syndromes (MDS) Patient Advocacy Roundtable was held in Amsterdam, The Netherlands. The goal of this roundtable, which was sponsored by Takeda Oncology, was to provide patient advocates with an opportunity to share their perspectives on the challenges faced by individuals living with higher-risk MDS. This publication shares the insights of patient advocacy community leaders regarding individuals with higher-risk MDS, including their advice for patients to support shared decision-making, patient education, and patient empowerment approaches. The...

Long‐term Results of Low‐intensity Chemotherapy with Clofarabine or Cladribine Combined with Low‐Dose Cytarabine Alternating with Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

Originally Published: 04/26/2021
Abstract Background The treatment of older patients with newly diagnosed acute myeloid leukemia (AML) using intensive chemotherapy is associated with treatment intolerance and poor survival. We evaluated two new lower‐intensity regimens with clofarabine (n=119) or cladribine (n=129) combined with low‐dose cytarabine (LDAC) alternating with decitabine. (Article Continues at Link)

RARA Agonist Plus Azacitidine Shows Encouraging Activity in Relapsed/Refractory AML

Originally Published: 04/25/2021
The novel agentSY-1425 combined with azacitidine appears to be active in retinoic acid receptor alpha (RARA) superenhancer–positive newly diagnosed and relapsed or refractory acute myeloid leukemia (AML), according to the results of a phase II trial presented at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.1 SY-1425 is targeted to the RARA gene, a novel target in AML. “There are hints here that this therapy may find a place with the right patient population who has relapsed and refractory AML,” said lead author Eytan M. Stein, MD, a hematologist/oncologist...

Isoform-specific and signaling-dependent propagation of acute myeloid leukemia by Wilms tumor 1

Originally Published: 04/20/2021
Highlights WT1 is an important factor for AML maintenance in multiple subtypes WT1 acts in an isoform- and AML-subtype-specific fashion WT1 binding to chromatin is in balance with early growth response factors Upregulation of expression is part of an interlinked oncogenic signaling network Summary Acute myeloid leukemia (AML) is caused by recurrent mutations in members of the gene regulatory and signaling machinery that control hematopoietic progenitor cell growth and differentiation. Here, we show that the transcription factor WT1 forms a major node in the rewired mutation-specific gene...

What's New? Foundation Update Newsletter April 2021

Originally Published: 04/20/2021

The development and clinical use of oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes: dawn of the total oral therapy era

Originally Published: 04/14/2021
Abstract Introduction Intravenous and subcutaneous hypomethylating agents have held a key role in myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia treatment. Following the approval of the cedazuridine/decitabine combination, ASTX727, as well as development of an oral formulation of azacitidine, CC-486, in the USA in 2020, these agents could gradually replace their injectable counterparts. Areas covered ASTX727 is approved for the treatment of adult patients with intermediate 1 or high risk MDS as well as those with chronic myelomonocytic leukemia based on...
Share with addtoany.com.